High-yield dividend stocks have been gaining momentum ahead of potential Fed rate cuts. Here's why these two high-yield ...

When Pfizer acquired Global Blood Therapeutics in October 2022, the flagship drug in the company’s portfolio was Oxbryta, a groundbreaking treatment that targets the root cause of sickle cell ...

Wilson celebrates the first U.S. patient to complete gene therapy for sickle cell, but says advocacy must continue.

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...

In September, Pfizer withdrew Oxbryta (voxelotor) for sickle cell disease, added via its $5.4 billion buyout of Global Blood Therapeutics in 2022. Starboard contended that Pfizer overpaid for its ...

SAN FRANCISCO, Oct. 31, 2024 /PRNewswire/ -- Pfizer, Inc. and Global Blood Therapeutics, Inc. were sued in San Francisco Superior Court where the plaintiff alleges the drug Oxbryta contributed to ...

A drug projected to have over $3B peak sales potential, Oxbryta was added to Pfizer's (PFE) portfolio following its $5B acquisition of Global Blood Therapeutics in 2022. "For large pharma ...

Read the research here. Among other issues, Pfizer in September recalled the sickle cell anemia treatment Oxbryta due to safety concerns. The drug was gained in the 2022 purchase of Global Blood ...

Pfizer last month abruptly decided to pull the centerpiece of the deal, sickle cell disease therapy Oxbryta, off global markets after new clinical data raised increased numbers of painful vaso ...

and pulling its sickle cell disease treatment Oxbryta due to deaths in its clinical trials. Smith did not make any specific prescriptions for Pfizer or its management at the presentation.

FILE PHOTO: Jeffrey Smith, Managing Member, CEO and CIO of Starboard Value, speaks during the 13D Monitor's Active-Passive Investor Summit in New York City, U.S., October 18, 2022. REUTERS/Brendan ...